Your Molecule
Your Molecule
Vaccine Formulation & Stability
Vaccine Formulation & Stability
Ensuring efficacy, stability, and usability for modern vaccine platforms.
Early risk identification to design stable, patient-ready drug products
Why vaccines need specialized formulation approach
Why vaccines need specialized formulation approach
Vaccines rely on immunogenic antigens that can be intrinsically unstable—protein antigens may denature, VLPs can lose structure, and adjuvants may precipitate or degrade. Thermal stress or repeated freeze-thaw cycles can reduce efficacy or trigger safety issues.
In real-world distribution, vaccines also face logistics challenges: inconsistent cold-chain availability, reconstitution in the field, and device incompatibilities. A robust formulation mitigates these risks, keeping vaccines potent, safe, and effective from R&D through distribution.
Explore our full modalities hub
Vaccines rely on immunogenic antigens that can be intrinsically unstable—protein antigens may denature, VLPs can lose structure, and adjuvants may precipitate or degrade. Thermal stress or repeated freeze-thaw cycles can reduce efficacy or trigger safety issues.
In real-world distribution, vaccines also face logistics challenges: inconsistent cold-chain availability, reconstitution in the field, and device incompatibilities. A robust formulation mitigates these risks, keeping vaccines potent, safe, and effective from R&D through distribution.
Explore our full modalities hub
Our expertise
Our expertise
We work with a diverse array of vaccine types:
● Live-attenuated / inactivated viruses — stabilize viral integrity while preserving antigenicity.
● Subunit protein vaccines — protect delicate proteins or conjugates through optimized buffer systems and stabilizing excipients.
● Virus-like particles (VLPs) — maintain particle conformation essential for immune response.
● Adjuvanted formulations — ensure compatibility with aluminum salts, emulsions, or novel adjuvants without compromising stability or immunogenicity.
● Viral vector vaccines — integrate capabilities from viral formulation programs to preserve infectivity and expression.
We work with a diverse array of vaccine types:
● Live-attenuated / inactivated viruses — stabilize viral integrity while preserving antigenicity.
● Subunit protein vaccines — protect delicate proteins or conjugates through optimized buffer systems and stabilizing excipients.
● Virus-like particles (VLPs) — maintain particle conformation essential for immune response.
● Adjuvanted formulations — ensure compatibility with aluminum salts, emulsions, or novel adjuvants without compromising stability or immunogenicity.
● Viral vector vaccines — integrate capabilities from viral formulation programs to preserve infectivity and expression.
Ready to talk about your bispecific formulation strategy?
Ready to talk about your bispecific formulation strategy?
Turning complex molecules into robust drug products
Key Focus Areas
-
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
How we support you
Formulation Development — Explore excipient combinations to maximize stability
Stability and temperature-stress programs — Tailored testing including accelerated, real-time, and freeze-thaw scenarios.
In-use Testing— Evaluate performance in clinical settings